MedPath

Clinical Trial News

Rinatabart Sesutecan Shows Promise in Heavily Pretreated Ovarian Cancer

  • Rinatabart sesutecan (Rina-S) demonstrated a 50% objective response rate in heavily pretreated ovarian cancer patients at a 120 mg/m2 dose.
  • Responses to Rina-S were observed across varying levels of folate receptor-alpha (FRα) expression, indicating broad potential.
  • A Phase 3 trial is planned to further assess the safety and efficacy of Rina-S at 120 mg/m2 in advanced ovarian cancer patients.
  • The Phase 1/2 trial showed manageable safety profile with infrequent dose reductions and no ocular toxicities, neuropathy, or ILD.

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366RecruitingPhase 1
ProfoundBio US Co.
Posted 12/7/2022

Lantheus' 177Lu-PNT2002 Shows Promise in Metastatic Castration-Resistant Prostate Cancer

  • Lantheus' 177Lu-PNT2002 met its primary endpoint in the SPLASH Phase 3 trial, demonstrating a significant improvement in radiographic progression-free survival compared to ARPI switch.
  • The trial showed a 38.1% Overall Response Rate for 177Lu-PNT2002 versus 12.0% for the ARPI switch arm, including a 9.3% Complete Response rate.
  • Patients treated with 177Lu-PNT2002 experienced a statistically significant improvement in time to reduction of health-related quality of life.
  • Interim Overall Survival data, adjusted for crossover, showed a hazard ratio of <1.00, suggesting a potential survival benefit with 177Lu-PNT2002.

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526Active, Not RecruitingPhase 3
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Posted 2/25/2021

Long-Term Data Show Durable Benefit of Immunotherapy in Metastatic Melanoma

  • A decade-long follow-up of the CheckMate 067 trial reveals that roughly half of metastatic melanoma patients treated with nivolumab and ipilimumab remain cancer-free.
  • The combination therapy demonstrates a sustained efficacy and safety profile, with no new long-term toxicity signals observed over the 10-year period.
  • The findings suggest that patients progression-free at three years have a high likelihood of remaining alive and disease-free at the 10-year mark.
  • Researchers suggest the long-term success may allow for reduced follow-up frequency for patients doing well after three to five years.

Cabozantinib/Atezolizumab Fails to Meet OS Endpoint in mCRPC, Regulatory Submissions Limited

  • The Phase III CONTACT-02 trial evaluated cabozantinib plus atezolizumab versus a second novel hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC).
  • While the combination showed a positive trend in overall survival (OS), it did not reach statistical significance (HR: 0.89; 95% CI: 0.72-1.10; P=0.296).
  • Ipsen will not pursue regulatory submissions for the cabozantinib/atezolizumab combination in mCRPC in countries outside the US and Japan, despite a statistically significant PFS benefit.
  • The combination demonstrated a statistically significant benefit in progression-free survival (PFS) and showed promising OS benefit in patients with liver and bone metastases.

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117Active, Not RecruitingPhase 3
Exelixis
Posted 6/30/2020

Keytruda Shows Sustained Survival Benefit in Advanced Melanoma After 10 Years

  • Ten-year follow-up data from the KEYNOTE-006 trial demonstrates a sustained overall survival (OS) benefit for Keytruda (pembrolizumab) compared to ipilimumab in advanced melanoma.
  • The 10-year OS rate for Keytruda was 34.0% versus 23.6% for ipilimumab, with Keytruda reducing the risk of death by 29% (HR=0.71).
  • Median OS for Keytruda was more than double that of ipilimumab (32.7 months versus 15.9 months), highlighting the long-term efficacy of pembrolizumab.
  • Keytruda has shown sustained survival benefits of five years or more across multiple cancer types, marking its transformative impact on cancer treatment.

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873RecruitingPhase 3
Merck Sharp & Dohme LLC
Posted 8/21/2018

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

NCT01866319CompletedPhase 3
Merck Sharp & Dohme LLC
Posted 8/28/2013

Daiichi Sankyo's DS-9606 Shows Early Promise in Advanced Solid Tumors Expressing CLDN6

  • DS-9606, a CLDN6-directed antibody-drug conjugate, demonstrates preliminary clinical activity in heavily pretreated patients with advanced solid tumors.
  • The Phase 1 trial of DS-9606 showed manageable safety profile with no dose-limiting toxicities observed across dose levels.
  • Early efficacy signals include confirmed objective responses in germ cell, gastric/esophageal, and non-small cell lung cancers.
  • Further evaluation is ongoing to determine the recommended dose for expansion and to assess DS-9606's potential across various CLDN6-expressing tumor types.

A Study of DS-9606a in Patients With Advanced Solid Tumors

NCT05394675RecruitingPhase 1
Daiichi Sankyo
Posted 5/31/2022

TAR-200 Shows High Complete Response Rate in BCG-Unresponsive NMIBC

  • TAR-200 monotherapy demonstrated an 84% complete response rate in patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ.
  • The SunRISe-1 phase 2b study evaluated TAR-200 alone or with cetrelimab, showing durable responses without reinduction in the TAR-200 monotherapy arm.
  • TAR-200 was well-tolerated, with most adverse events being grade 1 or 2, supporting its prioritized development as a monotherapy for high-risk NMIBC.
  • These results offer a potential bladder-sparing alternative for patients who are ineligible or unwilling to undergo radical cystectomy, addressing a critical unmet need.

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764RecruitingPhase 3
Janssen Research & Development, LLC
Posted 4/9/2024

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 3/23/2023

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT04919512Active, Not RecruitingPhase 2
Janssen Research & Development, LLC
Posted 7/7/2022

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 12/7/2020

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Active, Not RecruitingPhase 2
Janssen Research & Development, LLC
Posted 12/18/2020

TAR-200 Demonstrates High Complete Response in BCG-Unresponsive Bladder Cancer

  • TAR-200 monotherapy achieved an 83.5% complete response rate in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC).
  • Durable complete responses were observed, with 82% of patients maintaining response after a median follow-up of 9 months, suggesting long-term efficacy.
  • The safety profile of TAR-200 was favorable, with low discontinuation rates due to treatment-related adverse events, supporting its potential as a monotherapy.
  • Cetrelimab monotherapy showed a 46.4% complete response rate, while the combination of TAR-200 and cetrelimab resulted in a 67.9% complete response rate.

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764RecruitingPhase 3
Janssen Research & Development, LLC
Posted 4/9/2024

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 3/23/2023

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT04919512Active, Not RecruitingPhase 2
Janssen Research & Development, LLC
Posted 7/7/2022

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 12/7/2020

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Active, Not RecruitingPhase 2
Janssen Research & Development, LLC
Posted 12/18/2020

LEAP-012 Trial: Lenvatinib, Pembrolizumab, and TACE Improve PFS in Intermediate-Stage HCC

  • The LEAP-012 trial demonstrated that combining lenvatinib and pembrolizumab with TACE significantly improves progression-free survival (PFS) in intermediate-stage hepatocellular carcinoma (HCC).
  • The combination therapy showed a median PFS of 14.6 months compared to 10 months with TACE alone, representing a 34% reduction in the risk of disease progression or death.
  • The objective response rate (ORR) was also higher in the combination arm (46.8%) compared to the placebo arm (33.3%), indicating enhanced clinical activity.
  • While treatment-related adverse events were more frequent in the combination arm, they were generally manageable, suggesting a favorable risk-benefit profile.

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957Active, Not RecruitingPhase 3
AstraZeneca
Posted 11/30/2018

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT04246177Active, Not RecruitingPhase 3
Merck Sharp & Dohme LLC
Posted 5/22/2020

IBI363 Receives FDA Designation, Advancing Treatment for Unspecified Condition

  • IBI363 has been granted a special designation by the FDA, marking a significant step in its development.
  • The designation aims to expedite the review process, potentially bringing IBI363 to patients sooner.
  • This regulatory milestone underscores the FDA's recognition of IBI363's potential in addressing an unmet medical need.
  • Further details regarding the specific designation type and its implications are anticipated to be disclosed.

Trending News

1

Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Phase 3 Trials, Reducing Injection Burden by 300 Doses Annually

2 days ago
2

Otsuka Pharmaceutical Secures Global Rights to HBM7020 BCMAxCD3 Bispecific T-Cell Engager for Autoimmune Diseases

a day ago
3

Japanese Startup's Urine-Based Cancer Test Detects Stage 0 Lung Cancer in Hokkaido Pilot Study

3 days ago
4

Novo Nordisk's Mim8 Shows Safe Direct Switch from Emicizumab in Phase 3b Hemophilia A Trial

2 days ago
5

EMA Recommends Approval of Alvotech's Biosimilar to Eylea for Eye Disorders

a day ago
6

Roche's NXT007 Achieves Zero Bleeds in Phase I/II Hemophilia A Trial, Advances to Phase III

a day ago
7

AltruBio's ALTB-268 Shows Promise in Preclinical Models of Inflammatory Diseases, Supporting Phase 2 UC Trial

a day ago
8

BioNxt Launches Feasibility Study for Oral Dissolvable Film Semaglutide Delivery

a day ago
9

XtalPi Secures $100 Million Partnership with Harvard's Gregory Verdine to Advance AI-Driven Drug Discovery

2 days ago
10

ITM and Debiopharm Initiate New Study Arm for CAIX-Targeted Theranostic in Clear Cell Renal Cell Carcinoma

a day ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy